Several phase 3 trials have demonstrated the utility of combining a CDK4/6 inhibitor, including ribociclib, palbociclib, abemaciclib and dalpiciclib, with endocrine therapy as a second-line treatment for HR-positive, HER2-negative advanced breast cancer [8–13]. The gene discussed is CDK4; the disease is breast cancer.